Rosalind Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Rosalind Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,480	Closed	-$50.8K	–	35
2024 Q2	$50.8K	Buy	+2,480	New	+$83K	0.04%	38

Other funds holding BTAI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Rosalind Advisors's BTAI Position: Q3 2024 in Review

Rosalind Advisors sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 2,480 shares — an estimated $50.8K sold.

Rosalind Advisors first reported a position in BTAI in Q2 2024 and held it in 1 quarter. The position peaked at $50.8K in Q2 2024. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

Rosalind Advisors reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
Rosalind Advisors sold 2,480 BioXcel Therapeutics shares in Q3 2024, an estimated $50.8K.
Rosalind Advisors first reported a position in BioXcel Therapeutics in Q2 2024 and held it in 1 quarter.
Rosalind Advisors's BioXcel Therapeutics position peaked at $50.8K in Q2 2024.
49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Rosalind Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.